Modeling strategies to increase population immunity and prevent poliovirus transmission in 2 high-risk areas in Northern India

Journal of Infectious Diseases

Volumn 210, Issue , 2014, Pages S398-S411

  Kalkowska, Dominika A ^a,b   Tebbens, Radboud J Duintjer ^a   Thompson, Kimberly M ^a,c  

^a Kid Risk Inc   (United States)

^b DELFT UNIVERSITY OF TECHNOLOGY   (Netherlands)

^c UNIVERSITY OF CENTRAL FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

eradication; IPV; OPV; polio; population immunity

Indexed keywords

ORAL POLIOMYELITIS VACCINE; POLIOMYELITIS VACCINE;

DISEASE TRANSMISSION; EPIDEMIC; HEALTH CARE POLICY; HIGH RISK POPULATION; HUMAN; IMMUNITY; INDIA; INFECTION PREVENTION; MODEL; POLIOMYELITIS; REVIEW; STRATEGIC PLANNING; TREATMENT PLANNING; VACCINATION; VIRAL CLEARANCE; ADOLESCENT; ADULT; AGED; CHILD; EPIDEMIOLOGY; FEMALE; IMMUNOLOGY; INFANT; MALE; MIDDLE AGED; NEWBORN; POLIOMYELITIS VIRUS; PRESCHOOL CHILD; PREVENTION AND CONTROL; STATISTICAL MODEL; TRANSMISSION; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; DISEASE TRANSMISSION, INFECTIOUS; FEMALE; HUMANS; INDIA; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; MODELS, STATISTICAL; POLIOMYELITIS; POLIOVIRUS; POLIOVIRUS VACCINES; YOUNG ADULT;

EID: 84910632491     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jit844     Document Type: Review

References (26)

1. Thompson KM, Pallansch MA, Duintjer Tebbens RJ, Wassilak SGF, Cochi SL. Modeling population immunity to support efforts to end the transmissio n of live polioviruses. Risk Anal 2013; 33: 647-63.
2. Thompson KM, Duintjer Tebbens RJ. Current polio global eradication and control policy options: Perspectives from modeling and prerequisites for ora l poliovirus vaccine cessation. Expert Rev Vaccines 2012; 11:449-59.
3. Thompson KM, Wallace GS, Duintjer Tebbens RJ, et al. Trends in the risk of U.S. polio outbreaks and poliovirus vaccine ava ilability for response. Public Health Rep 2012; 127:23-37.
4. World Health Organization. Polio vaccines and polio immunization in the pre-eradication era: WHO position paper-recommendations. Vaccine 2010; 28:6943-4.
5. Thompson KM, Pallansch MA, Duintjer Tebbens RJ, Wassilak SGF, Cochi SL. Pre-eradication national vaccine policy options for poliovirus infection and disease control. Risk Anal 2013; 33:516-43.
6. Nathanson N, Kew OM. From emergence to eradication: The epidemiology of poliomyelitis deconstructed. Am J Epidemiol 2010; 172: 1213-29.
7. Alexander LN, Seward JF, Santibanez TA, et al. Vaccine policy changes and epidemiology of poliomyelitis in the United States. JAMA 2004; 292:1696-701.
8. Duintjer Tebbens RJ, Pallansch MA, Kim JH, et al. Oral poliovirus vaccine evolution and insights relevant to modeling the risks of circulating vaccine-derived polioviruses. Risk Anal 2013; 33: 680-702.
9. Duintjer Tebbens RJ, Pallansch MA, Chumakov KM, et al. Expert review on poliovirus immunity and transmission. Risk Anal 2013; 33:544-605.
10. Duintjer Tebbens RJ, Pallansc h MA, Chumakov KM, et al. Review and assessment of poliovirus immunity and transmission: Synthesis of knowledge gaps and identification of research needs. Risk Anal 2013; 33:606-46.
11. Kalkowska DA, Duintjer Tebbens RJ, Thompson KM. Modeling strategies to increase population immunity and prevent poliovirus transmission in the high-risk area of northwest Nigeria. J Infect Dis 2014; 210 (su ppl 1):S412-23.
12. World Health Organization. Transmission of wild poliovirus type 2-Apparent global interruption. Wkly Epidemiol Rec 2001; 76:95-7.
13. World Health Organization. India records one year without polio cases [news release]. http://www.who.int/mediacentre/news/releases/2012/polio-20120113/en/index.html. Accessed 28 August 2013.
14. US Census Bureau. State and county quick facts. http://quickfacts.census.gov/qfd/states/00000.html. Accessed 28 August 2013.
15. Government of India. 2011 census data. Office of the General & Census Commission, Ministry of Home Affairs, Government of India, 2013. http://censusindia.gov.in. Accessed 28 August 2013.
16. Duintjer Tebbens RJ, Pallansch MA, Kalkowska DA, et al. Characterizing poliovirus transmission and evolution: Insights from modeling experiences with wild and vaccine-related polioviruses. Risk Anal 2013; 33:703-49.
17. Duintjer Tebbens RJ, Kalkowska DA, Wassilak SGF, Pallansch MA, Cochi SL, Thompson KM. The potential impact of expand ing target age groups for polio immunization campaigns. BMC Infect Dis 2014; 14:45.
18. Estívariz CF, Pallansch MA, Anand A, et al. Poliovirus vaccination options for achieving eradication and securing the endgame. Curr Opin Virol 2013; 3:309-15.
19. Global Polio Eradication Initiative. Cases of wild poliovirus by country/year. http://www.polioeradication.org/Dataandmonitoring/Poliothisweek/Wildpolioviruslist.aspx. Accessed 1 September 2013.
20. Grassly NC, Fraser C,Wenger J, et al. New strategies for the elimination of polio from India. Science 2006; 314:1150-3.
21. T hompson KM, Duintjer Tebbens RJ. National choices related to inactivated poliovirus vaccine, innovation, and the end game of global polio eradication. Expert Rev Vaccine 2014; 13:221-34.
22. Thompson KM , Duintjer Tebbens RJ. Modeling the dynamics of oral poliovirus vaccine cessation. J Infect Dis 2014; 210(suppl 1): S475-84.
23. Global Polio Eradication Initiative. Polio eradication & endgame strategic plan: 2013- 2018. Geneva: WHO, 2010. http://www.polioeradication.org/resourcelibrary/strategyandwork.aspx. Accessed 1 November 2013.
24. Thompson KM, Duintjer Tebbens RJ. The case for cooperation in managing and maintaining the end of poliomyelitis: Stockpile needs and coordinated OPV cessation. Medscape J Med 2008; 10:190.
25. Anis E, Kopel E, Singer S, Kaliner E, et al. Insidious reintroduction of wild poliovirus into Israel, 2013. Euro Surveil 2013; 18:pii=20586.
26. Duintjer Tebbens RJ, Thompson KM. Priority shifting and the dynamics of managing eradicable infectious diseases. Manage Sci 2009; 55:650-63.